Regeneron Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US75886F1075

SecurityREGN / Regeneron Pharmaceuticals, Inc.
InstitutionBLACKROCK ADVANTAGE GLOBAL FUND, INC. - BLACKROCK ADVANTAGE GLOBAL FUND, INC. Investor A
Latest Disclosed Ownership992 shares
Latest Disclosed Value $ 520,800
BLACKROCK ADVANTAGE GLOBAL FUND, INC. - BLACKROCK ADVANTAGE GLOBAL FUND, INC. Investor A reports 55.49% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On August 28, 2025 - BLACKROCK ADVANTAGE GLOBAL FUND, INC. - BLACKROCK ADVANTAGE GLOBAL FUND, INC. Investor A filed a NPORT-P form disclosing ownership of 992 shares of Regeneron Pharmaceuticals, Inc. (US:REGN) valued at $520,800 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 638 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 55.49% during the quarter. The current value of the position is $745,557 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-28 2025-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 992 354 55.49 521 28.71 0.1100
2025-05-28 2025-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 638 380 147.29 405 120.77 0.0909
2025-02-25 2024-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 258 -112 -30.27 184 -52.84 0.0494
2024-11-26 2024-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 370 -368 -49.86 389 -49.94 0.0994
2024-08-26 2024-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 738 371 101.09 776 119.55 0.2027
2024-05-28 2024-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 367 -12 -3.17 353 6.33 0.0922
2024-02-26 2023-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 379 -31 -7.56 333 -1.48 0.0878
2023-11-28 2023-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 410 -42 -9.29 337 4.01 0.0921
2023-08-25 2023-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 452 0 0.00 325 -12.67 0.0824
2023-05-26 2023-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 452 0 0.00 371 13.80 0.0966
2023-02-24 2022-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 452 -384 -45.93 326 -43.30 0.0885
2022-11-25 2022-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 836 429 105.41 576 139.58 0.1688
2022-08-25 2022-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 407 0 0.00 241 -15.49 0.0628
2022-05-26 2022-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 407 -135 -24.91 284 -16.96 0.0617
2022-02-25 2021-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 542 -480 -46.97 342 -44.66 0.0691
2021-11-24 2021-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 1,022 741 263.70 618 296.15 0.1319
2021-08-26 2021-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 281 -453 -61.72 157 -55.04 0.0319
2021-05-27 2021-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 734 -382 -34.23 347 -35.62 0.0804
2021-02-25 2020-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 1,116 374 50.40 539 29.88 0.1279
2020-11-25 2020-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 742 -602 -44.79 415 -50.48 0.1085
2020-08-27 2020-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 1,344 693 106.45 838 164.35 0.2264
2020-06-01 2020-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 651 -41 -5.92 318 22.39 0.1002
2020-02-27 2019-12-31 NP Regeneron Pharmaceuticals EC 75886F107 692 -49 -6.61 260 26.34 0.0601
2019-11-27 2019-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 741 741 206 0.0486
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.